How to cite this article: Le Goff C, Cormier-Daire V. 2012. From tall to short: The role of TGFβ signaling in growth and its disorders. Am J Med Genet Part C Semin Med Genet.
From tall to short: The role of TGFβ signaling in growth and its disorders†
Article first published online: 12 JUL 2012
Copyright © 2012 Wiley Periodicals, Inc.
American Journal of Medical Genetics Part C: Seminars in Medical Genetics
Special Issue: New Topics in the Skeletal Dysplasias
Volume 160C, Issue 3, pages 145–153, 15 August 2012
How to Cite
Le Goff, C. and Cormier-Daire, V. (2012), From tall to short: The role of TGFβ signaling in growth and its disorders. Am. J. Med. Genet., 160C: 145–153. doi: 10.1002/ajmg.c.31337
- Issue published online: 19 JUL 2012
- Article first published online: 12 JUL 2012
- transforming growth factor-β;
- Marfan syndrome
The acromelic dysplasia group is characterized by short stature, short hands and feet, stiff joint, and “muscular” build. Four disorders can now be ascribed to this group, namely Weill–Marchesani syndrome (WMS), geleophysic dysplasia (GD), acromicric dysplasia (AD), and Myhre syndrome (MS). Although closely similar, they can be distinguished by subtle clinical features and their pattern inheritance. WMS is characterized by the presence of dislocation of microspherophakia and has autosomal dominant or recessive mode of inheritance. GD is the more severe one, with a progressive cardiac valvular thickening, tracheal stenosis, bronchopulmonary insufficiency, often leading to an early death. AD has an autosomal dominant mode of inheritance, distinct facial and skeleton features (a hoarse voice and internal notch of the femoral head). Finally, MS is sporadic, characterized by prognathism, deafness, developmental delay, thickened calvarium, and large vertebrae with short and large pedicles. We first identified mutations in Fibrillin-1 (FBN1) in the dominant form of WMS and then mutations in A Disintegrin-like And Metalloproteinase domain with ThromboSpondin type 1 repeats 10 (ADAMTS10) in the recessive form of WMS. The function of ADAMTS10 is unknown but these findings support a direct interaction between ADAMTS10 and FBN1. We then identified mutations in ADAMTSL2 in the recessive form of GD and a hotspot of mutations in FBN1 in the dominant form of GD and in AD (exon 41–42, encoding TGFβ binding protein-like domain 5 (TB5) of FBN1). The function of ADAMTSL2 is unknown. Using a yeast double hybrid screen, we identified latent transforming growth factor-β (TGFβ) binding protein 1 as a partner of ADAMTSL2. We found an increased level of active TGFβ in the fibroblast medium from patients with FBN1 or ADAMTSL2 mutations and an enhanced phosphorylated SMAD2 level, allowing us to conclude at an enhanced TGFβ signaling in GD and AD. Finally, a direct interaction between ADAMTSL2 and FBN1 was demonstrated suggesting a dysregulation of FBN1/ADAMTSL2 interrelationship as the underlying mechanism of the short stature phenotypes. Using exome sequencing in MS probands, we identified de novo SMAD4 missense mutations, all involving isoleucine residue at position 500, in the MH2 domain. In MS fibroblasts, we found decreased ubiquitination level of SMAD4 and increased level of SMAD4 supporting a stabilization of SMAD4 protein. Functional SMAD4 is required for canonical signal transduction through the oligomerization with phosphorylated SMAD2/3 and SMAD1/5/8. We therefore studied the nuclear localization of mutant SMAD complexes and found that the complexes translocate to the nucleus. We finally observed a decreased expression of downstream TGFβ target genes supporting impaired TGFβ driven transcriptional control in MS. Our findings support a direct link between the short stature phenotypes and the TGFβ signaling. However, the finding of enhanced TGFβ signaling in Marfan phenotypes supports the existence of yet unknown mechanisms regulating TGFβ action. © 2012 Wiley Periodicals, Inc.